Last reviewed · How we verify
NCT07141316
Effects of Blood Flow Restriction Combined With Electrostimulation After Knee Arthroplasty
NA trial testing Blood flow restriction combined with electrostimulation. in Osteo Arthritis Knee in 60 participants. Participants enrolled and being followed up; not accepting new ones.
10 April 2026
Quick facts
| Lead sponsor | University of Pavia |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 10 July 2025 |
| Primary completion | 10 April 2026 |
| Estimated completion | 10 April 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Blood flow restriction combined with electrostimulation.
Conditions studied
- Osteo Arthritis Knee — all drugs for Osteo Arthritis Knee →
Sponsor
University of Pavia
Who can join
Adults 60 to 85, any sex, with Osteo Arthritis Knee. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn whether blood flow restriction (BFR) combined with electrostimulation (ES) can improve the postoperative course of patients undergoing total knee arthroplasty. The main questions it aims to answer are: Immediately after surgery, do BFR combined with ES increase quadriceps strength? Do they also improve the functional abilities of patients? Researchers will compare BFR combined with ES to ES alone, to see if there are differences. Participants will carry out a daily session of BFR+ ES or ES alone for six working days after surgery
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07141316
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Osteo Arthritis Knee
Currently open trials in the same condition.
- NCT07258693 — Multimodal Treatment of Knee Osteoarthritis: Therapeutic Exercise and Noninvasive Neuromodulation (NESA) Versus Therapeu · NA · active not recruiting
- NCT06485843 — An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Jo · Phase 2 · recruiting
- NCT06965946 — Intermittent Hypoxia-Hyperoxia Combined With Physical Therapy for Knee Osteoarthritis · NA · recruiting
- NCT06058169 — Effects of Home Base Whole-body Vibration in Osteoarthritis. (VIBE-Rx2) · NA · recruiting
- NCT06257537 — Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis · Phase 2 · recruiting
Other University of Pavia trials
Trials by the same sponsor.
- NCT07491536 — Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis · NA · recruiting
- NCT07421128 — The Pause, Learn, and Activate Yourself (PLAY) · NA · not yet recruiting
- NCT07199712 — Ozone Therapy for Oral Mucositis in Patients Receiving Head and Neck Cancer Radio- and Chemotherapy · NA · completed
- NCT07088653 — Comparison of 0.12% Chlorhexidine and MicroRepair ABX Mouthwash in Gingivitis Management · NA · completed
- NCT07140146 — Trehalose vs Glycine Air-Polishing in Peri-Implant Mucositis Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07141316 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pavia
- Last refreshed: 26 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07141316.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing